

By stipulation of Plaintiff Toby Henry and Defendants Endo Health
 Solutions Inc.; Endo Pharmaceuticals Inc.; Teva Pharmaceuticals USA, Inc.;
 Angelini Pharma Inc.; Angelini; Angelini LaboPharm LLC; and Gruppo Angelini,
 and for good cause shown,

5 IT IS HEREBY ORDERED that Plaintiff shall file his amended complaint
6 on or before March 15, 2018. This amended complaint due on or before March 15,
7 2018 will not affect Plaintiff's right to amend as a matter of course under Federal
8 Rule of Civil Procedure 15(a)(1)(B).

9 IT IS HEREBY ORDERED that these Defendants are granted an extension
10 of time to answer or otherwise respond to Plaintiff's Complaint, pending the filing
11 of Plaintiff's forthcoming amended complaint which shall be filed on or before
12 March 15, 2018.

IT IS HEREBY ORDERED that these Defendants shall answer or otherwise
respond to Plaintiff's forthcoming amended complaint no later than 14 days after
its filing.

17 Dated: March 12, 2018

16

18

19

20

21

22

23

24

25

26

27

28

Troy L. Nunley United States District Judge